GMAB, is a biotechnology company known for its innovative antibody therapeutics. Established in 1999 and based in Copenhagen, ...
Equities research analysts at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Genmab A/S ...
Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...
Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $25.00. The ...
Assetmark Inc. lowered its position in Genmab A/S (NASDAQ:GMAB – Free Report) by 78.1% during the fourth quarter, Holdings ...
Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in ...
Fintel reports that on March 11, 2025, William Blair upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform ...
Genmab A/S has a trailing 12 month Price to Earnings (P/E) ratio of 11.6 while the S&P 500 average is 29.3 Its forward ...
Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their ...
Genmab (GMAB – Research Report) received a Buy rating and price target from William Blair analyst Matt Phipps today. The company’s shares ...
Genmab A/S said that Johnson & Johnson has decided not to exercise its option to obtain a worldwide license for the ...
The decision comes after Genmab provided J&J with data from a clinical proof-of-concept study, which included a head-to-head comparison with DARZALEX FASPRO® (daratumumab and hyaluronidase fihj) in ...